Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

BACKGROUND: The lipid-lowering and positive cardiovascular effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are more widely used in the lipid-lowering management of individuals with high cardiovascular risk. As real-world data are s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Laurenz T., Hochfellner, Daniel A., Knoll, Lisa, Pöttler, Tina, Mader, Julia K., Aberer, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070307/
https://www.ncbi.nlm.nih.gov/pubmed/33894772
http://dx.doi.org/10.1186/s12933-021-01283-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070307/
https://www.ncbi.nlm.nih.gov/pubmed/33894772
http://dx.doi.org/10.1186/s12933-021-01283-w

Ejemplares similares